65,437 trials
Low Tension Glaucoma
Primary: Change From Baseline in Raw Intraocular Pressure (IOP) by Visit — -3.20; -3.12; -3.22; -3.43 mmHg
Advanced Dupuytren's Disease
Primary: Reduction in Primary Joint Contracture to 5° or Less — 44.4; 4.8 Percentage of Joints — p=<.001
Dupuytren's Contracture
Primary: Clinical Success (Reduction in Contracture to 5° or Less) of the Primary Joint After the Last Injection — 64; 6.8 Percentage of Joints — p=<0.001
Advanced Dupuytren's Disease
Primary: Reduction in Contracture to 5° or Less — 41.9 Percentage of joints
Schizophrenia
Primary: Median Time to Discontinuation for Any Reason (Excluding Sponsor Decision) — 644.50; 677.50 Days — p=0.612
Advanced Dupuytren's Disease
Primary: Reduction in Contracture to 5° or Less — 52.7 percentage of joints
Pertussis · Tetanus · Diphtheria
Primary: Number of Participants Reporting A Solicited Injection Site or Systemic Reactions Within 7 Days Following Vaccination With Adacel® or Boostrix® — 273; 257; 5; 4…
Prostate Cancer
Primary: Participants With Markedly Abnormal Change in Vital Signs and Body Weight — 9; 4; 3; 3 participants
HIV Infections
Primary: Change From Baseline in Human Immunodeficiency Virus (HIV-1) Viral Load (Ribonucleic Acid [RNA]) — -0.890; -1.194; -0.953; -0.604 log10 copies/mL
Coronary Artery Disease
Primary: Ischemia Driven Target Lesion Failure (TLF) — 4.2; 6.8 Percentage of participants
Lung Cancer · Chemotherapy-Induced Thrombocytopenia · Non-Small Cell Lung Cancer
Primary: Number of Participants With Adverse Events — 12; 16; 18; 14 Participants
Coronary Disease · Coronary Artery Disease · Coronary Restenosis
Primary: In-stent Late Loss (LL) — 0.39; 0.19 millimeters
Attention Deficit Hyperactivity Disorder
Primary: Change From Baseline to 24 Weeks in the Conners' Adult Attention Deficit Hyperactivity Disorder Rating Scale - Investigator Rated: Screening Version (CAARS-Inv:SV) Total…
Tourette Syndrome
Primary: Mean Change From Baseline in Total Tic Score of the Yale Global Tic Severity Scale — -7.17; -7.16 score on a scale — p=0.996
Partial Epilepsies · Partial Onset Seizures
Primary: Number of Subjects With at Least One Adverse Event During the Treatment Period (up to 7 Days) — 17; 42; 20 subjects